Dec 05, 2025

Cell-penetrating peptides (CPPs) are short oligopeptides, typically composed of 8 to 30 amino acids ^[1], that can efficiently cross the plasma membrane and be internalized by living cells. Also known as protein transduction domains (PTDs), CPPs have been widely investigated for their ability to deliver bio-macromolecules—including proteins, nucleic acids, and therapeutic agents—into cells, thereby enhancing drug bioavailability and overcoming biological barriers ^[2]. Based on their physicochemical properties, CPPs are broadly classified into three categories: cationic (positively charged), amphipathic, and anionic (negatively charged). These classifications reflect not only differences in charge and hydrophobicity but also distinct mechanisms of cellular uptake.

1. Category and characteristic of CPPs

Cationic (positively charged) CPPs

Positively charged CPPs typically carry a net positive charge under physiological conditions, largely due to the abundance of lysine (Lys) and arginine (Arg) residues in their sequences. These cationic amino acids facilitate interaction with negatively charged components—such as phospholipids and glycoproteins—on the cell membrane, promoting cellular uptake through endocytosis or direct translocation ^[3]. Importantly, studies suggest that cell-penetrating efficiency in this class is driven primarily by overall charge density rather than specific sequence motifs ^[4]. For example, increasing the length of oligoarginine chains generally enhances cellular internalization—but at the cost of elevated cytotoxicity. Striking an optimal balance between membrane permeability and biocompatibility is therefore critical for therapeutic applications.

Amphipathic CPPs

Among the earliest discovered classes of CPPs, amphipathic peptides contain both cationic and hydrophobic amino acid residues within their sequences. The cationic domains interact with negatively charged membrane components—similar to positively charged CPPs—while the hydrophobic regions insert into lipid bilayers, inducing structural rearrangements that facilitate cellular entry ^[5]. For this class, the spatial arrangement and relative proportion of hydrophobic and cationic residues must be precisely engineered to maximize cell-penetrating efficiency while minimizing cytotoxicity.

Anionic (negatively charged) CPPs

These peptides incorporate multiple acidic amino acid residues, resulting in a net neutral or negative charge. Despite the electrostatic repulsion expected from the negatively charged extracellular membrane surface, certain anionic CPPs are nevertheless capable of efficient cellular uptake — though their precise internalization mechanism remains incompletely understood.

2. Unlocking Therapeutic Potential: Key Applications of CPPs

Cell-penetrating peptides (CPPs) offer broad therapeutic utility due to their unique ability to traverse biological membranes. One of their most promising applications is in drug delivery: CPPs can serve as efficient vectors to transport biopharmaceuticals across formidable physiological barriers such as the blood-brain barrier (BBB) and plasma membranes. This capability is especially valuable in tumor-targeted therapies, where intracellular delivery of therapeutics is critical. Importantly, their use extends beyond conventional platforms like peptide-drug conjugates (PDCs) and lipid nanoparticles (LNPs); for example, polyarginine 9R-mediated siRNA delivery has demonstrated efficacy in models of prostate cancer ^[6].

In addition to targeted delivery, CPPs can significantly enhance drug bioavailability. They have been shown to improve buccal absorption of macromolecules ^[7] and increase oral bioavailability of poorly permeable compounds — offering a non-invasive route for delivering peptide- and protein-based therapeutics that would otherwise require injection.

Furthermore, certain CPPs function not only as delivery vehicles but also as active pharmaceutical ingredients (APIs), combining membrane-penetrating activity with inherent biological effects. This dual functionality enables streamlined therapeutic design, reducing the need for separate carrier systems while maintaining or even enhancing pharmacological potency.

3. From Promise to Reality: Addressing Challenges and Solutions

Limited Half-Life, Stability, and Biodistribution:

CPPs typically exhibit short half-lives and poor stability—a common limitation of peptide therapeutics—due to rapid proteolytic degradation, renal clearance, and/or nonspecific accumulation in organs like the kidneys and lungs. These pharmacokinetic challenges significantly restrict their clinical translation, contributing to the absence of FDA-approved CPP-based drugs to date.

To address these limitations, several biochemical engineering approaches have been developed:

• Terminal modifications (e.g., N-terminal acetylation, C-terminal amidation) to block exopeptidase degradation
• D-amino acid substitution to evade endogenous proteases
• Backbone alteration with non-natural chemical groups to enhance metabolic stability
• Conformational restraint to reduce protease susceptibility
• Stapling/stitching via side-chain crosslinking to rigidify peptide structure

Lack of Target Selectivity:

Most CPPs display minimal specificity for diseased tissues over healthy cells. This non-selective uptake can result in off-target delivery, potentially triggering systemic toxicity and limiting therapeutic safety — a major barrier to clinical adoption.

To enhance spatial precision and reduce off-target effects, several targeting strategies have been developed:

• Conjugation with homing ligands — including small molecules, peptides, or full-length antibodies — to guide CPPs toward receptors overexpressed on target cells.
• Use of tumor-homing cationic CPPs, such as MT23 and BR2, which preferentially accumulate in malignant tissues due to enhanced electrostatic interactions with anionic cancer cell membranes.
• Fusion with RGD motifs — containing the Arg-Gly-Asp sequence — to target integrin αvβ3, commonly upregulated in tumor vasculature and metastatic cells.
• Antibody-CPP conjugates — combining the high specificity antibodies with the delivery power of CPPs to achieve lesion-localized payload release.
• Design of activatable (“smart”) CPPs — engineered to remain inert in circulation and only activate membrane translocation in response to disease-specific triggers, minimizing uptake in healthy tissues.

Limited Potency at Physiological Concentrations:

Many CPPs show their powerful penetrating activity only on a high concentration (＞10 μM), which is hardly acceptable in clinical trials. This is another important reason for preferring local administration of CPP-based pharmaceutical ^[8].

• Tandem duplication of some CPPs sequence can sometime show significant penetrating activity enhancement using much lower concentration.
• After endocytosis, a significant amount of the CPPs-cargo is trapped in the endosome and is degraded unless it escapes from the endosome to the cytosol before the lysosome fusion. Efficient endosomal escape is vital to reduce the administrative dose. One of the strategies is introducing His, which contains the imidazole group, into the CPPs sequence. Multiple His sequence can act as a proton sponge during endosomal acidification, and thus allowing the cargo molecular to escape from the endosome ^[9]. Using fusogenic peptides or conjugating fatty acid chains to CPPs are another two ways to improve the cellular uptake and endosomal escape.

CPPs exhibit promising biological activities including antimicrobial, antiviral and antitumor effects. GenScript offers high-purity CPP products for research applications, along with other therapeutic peptides for cancer treatment such as CEF pool peptides ^[10]. For more peptide products, please refer to the table below.

Explore Our Full Product Catalog: Access a comprehensive range of peptide products for diverse needs.

Discover Custom Peptide Services: Learn about tailored synthesis options designed to meet your unique requirements.